Skip to main content
Skip to main content
CTEV logo

Claritev Corporation (CTEV) Stock Analysis

$30.12 -$0.27 (-0.89%) |Avoid · 21
Signals are mixed — the Council read leans Split View (42/100) while the AI fundamental score is 21/100 (grade F); the two lenses disagree, so weigh the breakdown below. Strongest signal: Ray Dalio bullish · Biggest watch-out: Izzy Englander bearish.
MCap: $513M| Vol: 189.0K| Target: $33.67 (+11.8%)|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Claritev Corporation (CTEV) trades at $30.12 with AI Score 21/100 (Grade F). Claritev Corporation provides data analytics and technology-enabled cost management solutions to the healthcare industry. Market cap: $513M, Sector: Healthcare.

Price as of Jul 20, 2026 · Last analyzed: May 10, 2026
Claritev Corporation provides data analytics and technology-enabled cost management solutions to the healthcare industry. The company focuses on reducing medical costs through data-driven insights and network-based services.

CTEV stock analysis for 2026: Analysts have set a consensus price target of $33.67 for Claritev Corporation, suggesting 11.8% upside from the current price of $30.12. The AI MoonshotScore is 21/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.

Watch the CTEV film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Split View 42/100 · C

CTEV: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.

How is this calculated? →
MoonshotScore · Growth Potential · 21/100
Business Quality
Moderate Is this a genuinely good business?
Financial Safety
Moderate Could this blow up on me?
Valuation
Weak Am I paying a fair price?
Growth Durability
Moderate Is the growth real and likely to last?
Momentum
Neutral Is the market already moving on this?
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Ken Griffin
Neutral
Jim Simons
Bearish
Izzy Englander
Bearish
Seth Klarman
Neutral
Moon AI
Bullish
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Weak
Margin of Safety
Undervalued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →

Why this analysis is different

  • A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
  • An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
  • Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Claritev Corporation (CTEV) Healthcare & Pipeline Overview

CEOTravis S. Dalton
Employees2,700
HeadquartersNew York City, NY, US
IPO Year2020

Claritev Corporation delivers data analytics and cost management solutions to the healthcare industry, leveraging technology to reduce medical costs and improve payment accuracy. With a focus on data-driven insights and network-based services, Claritev serves national and regional insurance companies, aiming to optimize benefit plan designs and clinical outcomes.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 10, 2026

What Is the Investment Thesis for CTEV?

As of May 10, 2026 — figures reflect the data available on that date.

Claritev Corporation operates in the growing healthcare cost containment market. With a market capitalization of $513M, the company's analytics-based services offer potential for growth as healthcare providers and insurers seek to reduce costs and improve efficiency. The company's gross margin of 61.1% indicates a strong ability to generate profit from its services. Key value drivers include the increasing demand for data-driven cost management solutions in healthcare and the company's ability to expand its customer base. A potential risk is the company's negative profit margin of -29.3%, which needs to be addressed for long-term sustainability. The beta of 0.54 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

CTEV Key Highlights

  • Market Cap of $513M reflects the company's current valuation in the healthcare information services sector.
  • Gross Margin of 61.1% indicates strong profitability from core services, suggesting efficient cost management.
  • Profit Margin of -29.3% highlights a need for improved cost control and revenue generation strategies.
  • Beta of 0.54 suggests lower volatility compared to the market, potentially appealing to risk-averse investors.
  • Services cater to national and regional insurance companies, providing a stable and recurring revenue stream.

Who Are CTEV's Competitors?

CTEV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
DNTH Dianthus Therapeutics, Inc. $101.00 -4.36% $4.22B
NRC National Research Corporation $21.41 -1.70% $483M 70
ACCD Accolade, Inc. $7.02 +0.00% $576M 55
KSIOF Kneat.com, Inc. $4.59 +0.00% $441M 63
SOPH SOPHiA GENETICS SA $6.33 +7.84% $435M 58
RSLBF RaySearch Laboratories AB (publ) $18.85 +11.87% $639M 57
PHR Phreesia, Inc. $10.68 -0.28% $660M 55
SLGCW SomaLogic, Inc. $0.09 -28.33% $396M 55

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CTEV's Key Strengths?

  • Strong expertise in data analytics and cost management.
  • Established relationships with major insurance companies.
  • Comprehensive suite of services covering payment and revenue integrity.
  • Technology-enabled solutions for efficient claims processing.

What Are CTEV's Weaknesses?

  • Negative profit margin (-29.3%) indicates financial challenges.
  • Reliance on the healthcare industry makes it susceptible to regulatory changes.
  • Limited geographic diversification.
  • Dependence on data accuracy and security.

What Could Drive CTEV Stock Higher?

  • Expansion of data and decision science services to drive revenue growth.
  • Strategic partnerships with healthcare providers to enhance service offerings.
  • Potential acquisitions of complementary businesses to expand market share.
  • Development of new technology solutions using AI and machine learning.
  • Continued focus on improving cost management and payment integrity for clients.

What Are the Key Risks for CTEV?

  • Financial-distress signal — its Altman Z-Score of -0.40 sits in the distress zone (elevated bankruptcy risk).
  • Negative profit margin (-29.3%) poses a risk to financial sustainability.
  • Changes in healthcare regulations and reimbursement policies could impact revenue.
  • Data security breaches and privacy concerns could damage reputation and incur costs.
  • Increasing competition from other healthcare information service providers.
  • Economic downturn affecting healthcare spending could reduce demand for services.

What Are the Growth Opportunities for CTEV?

  • Expansion of Data and Decision Science Services: Claritev can expand its data and decision science services to offer more sophisticated analytics solutions. The market for healthcare analytics is projected to reach $45 billion by 2028, driven by the need for better insights into patient outcomes and cost management. By leveraging its existing data assets and expertise, Claritev can develop predictive and prescriptive analytics tools that drive optimized benefit plan design and improve clinical outcomes. Timeline: Ongoing.
  • Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with healthcare providers can enhance Claritev's service offerings and expand its market reach. Collaborating with providers allows Claritev to integrate its solutions directly into clinical workflows, improving the accuracy and efficiency of cost management processes. These partnerships can also provide access to valuable data and insights, further enhancing the company's analytics capabilities. Timeline: Ongoing.
  • Geographic Expansion: Claritev can expand its services to new geographic markets, both domestically and internationally. The demand for healthcare cost management solutions is global, and Claritev's expertise can be applied to address similar challenges in other countries. By targeting regions with high healthcare costs and complex regulatory environments, Claritev can tap into new revenue streams and diversify its customer base. Timeline: Upcoming.
  • Development of New Technology Solutions: Investing in the development of new technology solutions can differentiate Claritev from its competitors and enhance its value proposition. This includes exploring AI and machine learning technologies to automate and improve the accuracy of claims processing and cost management. By staying at the forefront of technological innovation, Claritev can attract new customers and retain existing ones. Timeline: Ongoing.
  • Acquisition of Complementary Businesses: Claritev can pursue strategic acquisitions of complementary businesses to expand its service offerings and market share. Acquiring companies with expertise in areas such as healthcare IT, data analytics, or payment processing can enhance Claritev's capabilities and create synergies that drive growth. This strategy can also provide access to new customers and markets. Timeline: Upcoming.

What Opportunities Does CTEV Have?

  • Expansion of data and decision science services.
  • Strategic partnerships with healthcare providers.
  • Geographic expansion to new markets.
  • Development of new technology solutions using AI and machine learning.

What Threats Does CTEV Face?

  • Increasing competition from other healthcare information service providers.
  • Changes in healthcare regulations and reimbursement policies.
  • Data security breaches and privacy concerns.
  • Economic downturn affecting healthcare spending.

What Are CTEV's Competitive Advantages?

  • Proprietary data analytics algorithms for cost management.
  • Established network of healthcare providers offering contracted discounts.
  • Expertise in payment and revenue integrity services.
  • Long-standing relationships with national and regional insurance companies.

What Does CTEV Do?

Founded in 1980 and formerly known as MultiPlan Corporation until its rebranding in February 2025, Claritev Corporation provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company's core offerings revolve around reducing medical costs through advanced data analytics, identifying claims over-charges, and negotiating reimbursements. Claritev also provides network-based services, offering contracted discounts with healthcare providers and outsourced network development and management. Its payment and revenue integrity services focus on identifying and removing improper charges, while also working to restore underpaid premium dollars. Additionally, Claritev offers data and decision science services, using modern data science methods to produce descriptive, predictive, and prescriptive analytics. These analytics drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care. The company serves a diverse clientele, including national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other entities involved in claim adjudication. Headquartered in New York, Claritev Corporation continues to evolve its solutions to meet the changing needs of the healthcare industry.

What Products and Services Does CTEV Offer?

  • Provides data analytics solutions for healthcare cost management.
  • Offers technology-enabled payment and revenue integrity services.
  • Reduces medical costs through data-driven algorithms and insights.
  • Detects claims over-charges and negotiates reimbursement.
  • Provides contracted discounts with healthcare providers.
  • Offers outsourced network development and management services.
  • Identifies and removes improper and unnecessary charges paid during the claim.
  • Restores and preserves underpaid premium dollars.

How Does CTEV Make Money?

  • Generates revenue through analytics-based services that reduce medical costs.
  • Provides network-based services offering contracted discounts with healthcare providers.
  • Offers payment and revenue integrity services to identify and remove improper charges.
  • Provides data and decision science services for optimized benefit plan design.

What Industry Does CTEV Operate In?

Claritev Corporation operates within the healthcare information services industry, which is experiencing growth due to increasing pressure to manage healthcare costs and improve outcomes. The industry is characterized by the adoption of data analytics and technology-enabled solutions to streamline processes and reduce inefficiencies. Claritev competes with other companies offering similar cost management and payment integrity services. The company's focus on data-driven insights and comprehensive solutions positions it to capitalize on the growing demand for healthcare cost containment strategies.

Who Are CTEV's Key Customers?

  • National and regional insurance companies
  • Blue Cross and Blue Shield plans
  • Provider-sponsored and independent health plans
  • TPAs (Third Party Administrators)
  • Self-insured health plans
AI Confidence: 67% Updated: May 10, 2026

How Claritev Corporation Is Valued

Claritev Corporation carries a market capitalization of $513M, placing it in the small-cap category. Relative to its peer group, CTEV's quantitative score of 21/100 is below the peer average of 62/100.

ROE 206%Key Financial Metrics

Return on equity for Claritev Corporation stands at 205.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.28 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -57.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9Financial Health

Claritev Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.40 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Claritev Corporation revenue of about $993.4M for fiscal 2026, with EPS near $-15.93. The estimate reflects 3 contributing analysts.

CTEV Financials

Fundamental Snapshot

Revenue Growth (FY)
+3.7%
Net Income Growth (FY)
+82.7%
EPS Growth (FY)
+83.0%
Free Cash Flow Growth (FY)
-16.8%
P/E (TTM)
5.0
Current Ratio
1.3

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Claritiv's recent insider buying suggests those in the know see value, a classic signal of potential upside. Think of it like Buffett buying Berkshire shares – confidence from the top.
  • Community sentiment seems to be shifting, with more users discussing potential partnerships and expansions. It's like the buzz around Tesla before the 2020 rally, a feeling of something big brewing.
  • The overall market perception of CTEV is improving, with more analysts mentioning them in positive contexts. Similar to how Apple's reputation grew with each innovative product launch.
  • Recent market developments suggest increased demand for Claritiv's services, potentially leading to revenue growth. It's reminiscent of the surge in demand for cloud computing during the pandemic.

Bear Case

  • Significant short interest indicates many believe CTEV is overvalued, creating potential downward pressure. It's like the skepticism surrounding subprime mortgages before the 2008 crash.
  • Community sentiment also reveals concerns about increased competition in Claritiv's sector. This is similar to the challenges faced by Blockbuster against Netflix, a shift in market dominance.
  • Market perception is mixed, with some questioning Claritiv's long-term sustainability. This is akin to concerns about dot-com companies during the early 2000s bubble.
  • Recent insider selling, while not always negative, could signal a lack of confidence in near-term prospects. It's a bit like executives selling shares before a major announcement, raising eyebrows.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026

CTEV Latest News

CTEV Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CTEV.

Price Targets

Consensus target: $33.67

CTEV MoonshotScore

21/100

What does this score mean?

The MoonshotScore rates CTEV 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.

Leadership: Travis S. Dalton

CEO

Travis S. Dalton is the CEO of Claritev Corporation, leading a team of 2700 employees. His background includes extensive experience in the healthcare technology and data analytics sectors. Prior to joining Claritev, Dalton held leadership positions at various healthcare companies, where he focused on developing and implementing innovative solutions to improve healthcare outcomes and reduce costs. He holds an MBA from a top-tier business school and a bachelor's degree in computer science.

Track Record: Since becoming CEO, Travis S. Dalton has focused on expanding Claritev's data and decision science services and strengthening its relationships with key clients. He has overseen the rebranding of the company from MultiPlan Corporation to Claritev Corporation in February 2025, signaling a renewed focus on innovation and growth. Dalton's strategic decisions have aimed to position Claritev as a leader in healthcare cost management and payment integrity.

CTEV Healthcare Stock FAQ

What does the AI Score mean for CTEV?

CTEV holds an AI Score of 21/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Claritev Corporation provides data analytics and technology-enabled cost management solutions to the healthcare industry. The company focuses on reducing medical costs through data-driven insights …

What does Claritev Corporation do?

Claritev Corporation provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers services that reduce medical costs through data-driven algorithms and insights, detecting claims over-charges and negotiating reimbursements.

What do analysts say about CTEV stock?

Analyst coverage of Claritev Corporation (CTEV) is limited based on available data. Key valuation metrics to consider include the company's market capitalization of $513M and its gross margin of 61.1%. However, the negative profit margin of -29.3% is a concern.

What are the main risks for CTEV?

The main risks for Claritev Corporation include its negative profit margin, which indicates financial instability. Changes in healthcare regulations and reimbursement policies could adversely affect revenue streams. Data security breaches and privacy concerns pose a threat to the company's reputation and could result in significant costs. Increasing competition from other healthcare information service providers could erode market share.

What are the key factors to evaluate for CTEV?

Claritev Corporation (CTEV) holds an AI score of 21/100 (low). Analysts target $33.67 (+12%). Not financial advice.

How frequently does CTEV data refresh on this page?

CTEV's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven CTEV's recent stock price performance?

Claritev Corporation (CTEV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong expertise in data analytics and cost management. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CTEV overvalued or undervalued right now?

Claritev Corporation (CTEV) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $33.67 (+12%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CTEV before investing?

Before investing in Claritev Corporation (CTEV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Financial data is limited to market cap, profit margin, and gross margin.
  • AI Insight is based on limited information.
Data Sources

Popular Stocks